An Overview of Clinical Trials in the Treatment of Resectable Hepatocellular Carcinoma

Surg Oncol Clin N Am. 2023 Jan;32(1):101-117. doi: 10.1016/j.soc.2022.07.008. Epub 2022 Nov 3.


Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death worldwide. Partial hepatectomy, one of a few curative therapeutic modalities, is plagued by high recurrence rate of up to 70% at 5 years. Throughout the past 3 decades, many clinical trials have attempted to improve HCC recurrence rate following partial hepatectomy using adjuvant and neoadjuvant treatment modalities such as antiviral therapy, brachytherapy, systemic chemotherapy, immunotherapy, transarterial chemoembolization and radioembolization, and radiotherapy. The goal of this review is to discuss the clinical trials pertaining to resectable HCC including surgical technique considerations, adjuvant, and neoadjuvant treatment modalities.

Keywords: Clinical trials; Hepatocellular carcinoma; Liver cancer.

Publication types

  • Review
  • Research Support, N.I.H., Extramural

MeSH terms

  • Carcinoma, Hepatocellular* / pathology
  • Carcinoma, Hepatocellular* / surgery
  • Chemoembolization, Therapeutic* / methods
  • Hepatectomy
  • Humans
  • Liver Neoplasms* / pathology
  • Liver Neoplasms* / surgery
  • Neoadjuvant Therapy